

## **FORMAL ANNOUNCEMENT – SALE OF SUBSIDIARY**

**Date:** July 11<sup>th</sup>, 2025

**To:** The Shareholders, Investors, and the Market

**From:** Meditrina Cyprus P.l.c.

**Subject:** Disposal of Subsidiary – Meditrina Pharmaceuticals S.r.l. - Romania

Meditrina Cyprus P.l.c. (the "Company"), listed on the MTF market of Cyprus Stock Exchange hereby announces that it has entered into a definitive agreement to divest 100% of its shareholding in its subsidiary, Meditrina Pharmaceuticals S.r.l. – Romania, to Fidia Farmaceutici S.p.A. – Italy, for a total consideration of 6.5M €, plus various earn-outs for the next two fiscal years, subject to customary closing conditions, regulatory approvals and business targets.

### **Strategic Rationale**

The divestment aligns with the Company's long-term strategic plan to sharpen its focus on its core business areas and reallocate resources to higher-growth opportunities. The decision to sell Meditrina Pharmaceuticals S.r.l. was made following a comprehensive business review aimed at enhancing shareholder value and operational efficiency.

Meditrina Pharmaceuticals S.r.l., while a profitable and well-run business, operates in a sector that is no longer core to our strategic direction. The proceeds from the sale will strengthen our balance sheet and provide additional capital to accelerate our expansion into new and emerging markets, to focus on the R&D of new products and to exploit new sectors in the health business.

We believe this transaction creates a win-win scenario: it allows Meditrina Pharmaceuticals S.r.l. to continue its growth trajectory under new ownership better aligned with its market focus, and it enables Meditrina Cyprus P.l.c. to redeploy capital toward areas with higher expected returns and innovation potential. Additionally, Meditrina Cyprus P.l.c. and Fidia Farmaceutici S.p.A. have agreed to explore potential avenues for strategic collaboration in selected international markets where Fidia Farmaceutici S.p.A. already maintains a well-established commercial presence.

### **Financial Impact**

The transaction is closed on July 10<sup>th</sup>, 2025. Further details about the financial impact will be disclosed in our next semester financial report.

### **Conclusion**

This divestiture marks a significant milestone in the execution of our transformation strategy. We remain committed to creating long-term value for our shareholders and believe this step positions us well for future growth and agility in a dynamic market environment.

Should you have any further questions or require additional information, please contact our Investor Relations department at [info.cyprus@meditrina.eu](mailto:info.cyprus@meditrina.eu).

#### About Meditrina Cyprus P.l.c

Meditrina Cyprus P.l.c. is the holding company of Meditrina Group, a group of companies operating in South Eastern Europe (with subsidiaries in Cyprus, Greece, Bulgaria, Romania and Moldova) specialized in the R&D, distribution, promotion and marketing of food supplements, medical devices, pharmaceuticals and cosmetics in the therapeutic areas of urology, gynecology and dermatology. Meditrina Cyprus P.l.c., a company incorporated under Cyprus law with the headquarters in Limassol, is listed at the MTF market of Cyprus Stock Exchange.

#### About Fidia Farmaceutici S.p.A.

Founded in Italy in 1946, a world leader in the research, development, manufacture and marketing of innovative products, particularly products containing hyaluronic acid and its derivatives, working in strategic areas such as joint care, skin care, eye care, specialty care and health & wellness care. Fidia has been producing hyaluronic acid from different sources and with various molecular weights for a range of applications for over 60 years (over 1,400 international patents, of which over 1,200 involve hyaluronic acid). The company has a production plant and R&D laboratories at Abano Terme (PD), where the company's head office is based, production plants in Paderno Dugnano (MI) and Monte Giberto (FM), as well as in Noto (SR), where there is also a specialized Research Unit. With over 1,700 employees worldwide, Fidia distributes its products in over 120 countries globally, through an established network of partners and distributors and with commercial subsidiaries in strategic markets such as the United States, Germany, Austria, Spain, France, Russia, Czech Republic, Slovakia, Romania, Poland, Egypt, Turkey and the META region.

RTPR, Romania acted as legal counsel for Meditrina Cyprus P.l.c. involving a team coordinated by Mihai Ristici (Partner) and Marina Fecheta-Giurgica (Senior Associate), closely assisted by Maria Luca (Associate).

#### On behalf of the Board

For Meditrina Cyprus PLC

